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Abstract 
Despite decades of industry innovation and regulatory efforts, the harmfulness of 
conventional cigarettes has not changed. There are several pitfalls in this area, including the 
long time lag before health impacts of product regulatory changes become apparent, the 
danger of consumers deriving false reassurance of lesser harm in the interim period, the 
lack of relevant expertise and the lack of an internationally agreed and evidence-based 
strategic approach. Articles 9 and 10 of the Framework Convention on Tobacco Control 
provide the potential for such a global strategy, and knowledge and research has increased 
significantly over recent years. However, there are huge opportunity costs in implementing 
product disclosure and regulatory strategies: most national regulators have very limited 
human and financial resources, which should be focused on other evidence-based tobacco 
control interventions. We believe therefore that it is now time to abandon the notion of 
safe or safer cigarettes while moving consumers towards cleaner nicotine products as soon 
as possible. In parallel to this, we recommend a number of other strategies be implemented 
including: reducing the appeal of all tobacco products, forbidding new tobacco products or 
brand variants being marketed without evidence of reduced harm, appeal or addictiveness, 
and developing a tobacco industry resourced, but industry independent, Framework 
Convention on Tobacco Control global repository to assist national regulators in 
understanding and regulating the products on their markets.  
Introduction 
Product regulation is the most complex and underdeveloped area of tobacco control, yet 
with 1 billion tobacco users worldwide, it could hold the key to rapid reductions in the 
mortality and morbidity wreaked by continuing tobacco use. The complexity arises because 
little is known outside the tobacco industry about the technologies and formulae involved in 
making individual products. What is established is that cigarettes are highly engineered and 
sophisticated products designed to give fingertip control of nicotine intake while masking 
unpleasant tastes and aromas; however, even crudely manufactured tobacco products, such 
as hand-rolled cigarettes, are widely used and highly addictive. All tobacco products are 
deadly but their harmfulness ranges dramatically. Nicotine is the key dependence-inducing 
component, but other attributes of tobacco and tobacco smoke play an important role in 
continued use1; indeed many tobacco users have not shown much willingness to switch to 
much less harmful nicotine products (although a policy to encourage such switching has not 
yet been rigorously pursued by any government).  
The key form of product regulation adopted for cigarettes in the last 50 years was the 
reduction of machine-based emission yields of smoke constituents (the ‘tar reduction’ 
strategy) achieved through filter ventilation. Despite evidence that machine yields of ‘light’ 
cigarettes did not reflect smokers' exposure,2 regulations to reduce machine-based yields 
and associated information on packs remain stubbornly in place in many areas of the world. 
This inertia may reflect, among other things, difficulties in overturning ineffective legislation, 
the lack of an agreed alternative strategy and/or the tobacco industry's influence on 
policymakers to maintain ineffective regulations. However, the WHO's Framework 
Convention on Tobacco Control (FCTC) has given cause for renewed optimism. Articles 9 and 
10 of the FCTC focus on product testing, measurement, regulation and disclosure3 and in 
November 2010 partial guidelines for these Articles were adopted at the Fourth Conference 
of the Parties.4 A new regulatory framework has also emerged in the USA, one of the few 
countries with the technical capacity and resources to undertake comprehensive regulation. 
In 2009, the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) gave 
the US Food and Drug Administration (FDA) the authority to regulate the manufacture, 
distribution and marketing of tobacco products to protect public health and this has already 
led to a number of actions being taken.  
This paper critiques past and present efforts to regulate tobacco products and makes 
recommendations for the future. Although tobacco product regulations are inextricably 
linked to product packaging and promotion, these aspects are covered in other papers in 
this issue and will not be discussed in detail here, although the implications of these 
important linkages will be briefly highlighted.  
Types of regulation 
Table 1 summarises extant product regulatory strategies for tobacco products, and we 
outline below a brief summary of the key strategies.  
Table 1  
Key extant product regulatory strategies 
Combustible tobacco products 
No clear differences in risk have yet been demonstrated across the range of popular 
combustible products, but the harmfulness of pipes and cigars appears to vary according to 
the degree of inhalation (eg, Rodriguez et al5). Most regulatory strategies in this area have 
focused on manufactured cigarettes, given that they are the most prevalent form of tobacco 
use worldwide and responsible for most of the deaths caused by tobacco use, rather than 
other combustible products, some of which are growing in popularity (such as hand-rolled 
cigarettes, cigars, pipes, waterpipes, kreteks, bidis, etc).  
Reducing harm and toxicity 
The tar reduction strategy arose in the 1960s and 1970s in the UK and USA when knowledge 
of smoking behaviour and the chemical characteristics of smoke was in its infancy. Initially 
through voluntary agreements with the tobacco industry, and later through legislative 
approaches in a number of different countries, maximum yields were set for tar emissions 
from cigarettes and, subsequently, nicotine and carbon monoxide. The failure of this 
approach and its manipulation by the tobacco industry has been widely documented 
elsewhere (eg, the report by the Royal College of Physicians6) so will not be covered in detail 
here. In short, the maximum yields were set using cigarette smoking machines and products 
were altered, predominantly by putting ventilation holes in the filter, to dilute the smoke. 
Humans compensated for the reduced delivery of the cigarettes by changing the way they 
smoked, including covering the holes.2 Levels of human exposure were therefore very 
similar across different yields of cigarettes and studies have failed to show any health 
benefits of smoking lower-yielding cigarettes.6 7 Nevertheless, the tar reduction strategy was 
a marketing success in that the market share of lower-yielding cigarettes increased 
markedly in most jurisdictions worldwide. This was partly due to very high-yielding products 
being taken off the market but also due to a very successful marketing strategy by the 
tobacco industry, using branding such as ‘light’ and ‘mild’ and colours to mislead consumers 
that there was a genuine advantage to health in smoking the lower-tar-yield products.  
Other industry innovations to reduce harm include charcoal filters, which are common in 
markets such as Japan, Venezuela and South Korea. These significantly reduce some toxic 
gas-phase emissions in cigarette smoke, and have been postulated as one of the reasons for 
the lower lung cancer rates of Japanese smokers (eg, Muscat et al8). Such filters also affect 
the flavour of cigarette smoke, which may explain why they have not become more 
prevalent. It is not yet known whether the emission reductions translate into reduced 
human exposure and disease risk.  
The tobacco market is a dynamic one with new products and brands being introduced 
regularly; for example, in the UK the number of new brands of manufactured cigarettes 
increased by 168% over a 10-year period between 1998 and 20089 and in the USA, an 
estimated 233 new products were introduced in 2008.10 In the USA, manufacturers of new 
or modified tobacco products are now required to submit a premarket application and 
obtain a market authorisation order before they can market new products.11 This is a useful 
attempt at regulation, primarily because it would allow for regulatory scrutiny prior to the 
product being introduced to the market and prior to consumer use. To some extent, this 
system also compels the regulatory agency to establish criteria for review and regulatory 
approval. A potential weakness of this approach is that nothing is required of manufacturers 
of products for which they can claim ‘substantial equivalence’ to ones that are already on 
the market. This would appear to allow further expansion of product variants and be a 
disincentive against producing reduced risk products. In addition, premarket regulatory 
approval might be perceived as regulatory ‘approval’ for tobacco products and may even 
have implications for regulatory liability.  
The tobacco industry has also developed a number of putatively reduced harm cigarettes 
and cigarette-like devices, such as those that heat rather than burn tobacco, some of which 
have been referred to as potential reduced exposure products (PREPs).12 Although some can 
result in reduced levels of key biomarkers, (eg, Breland et al13) they have not been 
demonstrated to significantly reduce the disease burden or addictive potential in 
comparison to usual cigarettes. Overall, these products have been market failures,14 with 
low levels of public awareness.15 
Reduced ignition propensity cigarettes 
A strategy gaining momentum worldwide at the behest of regulators is the development of 
reduced ignition propensity (RIP) cigarettes designed to reduce the fire hazard caused by 
smouldering cigarettes. In 2005, Canada became the first country to require RIP cigarettes 
following the adoption of a minimal fire safety standard in the state of New York in the USA. 
Ignition propensity can be reduced in a number of ways and tests have shown that RIP 
cigarettes are significantly less likely to cause fires if left unattended.16 No formal evaluation 
has yet been undertaken but preliminary data from New York and other states indicated a 
reduction in the incidence of fires.17 While the tobacco industry protested for many years 
that RIP cigarettes could either not be developed or be acceptable to consumers,18 
compliance has been high. The WHO Tobacco Product Regulation Study Group (WHO 
TobReg) has recommended that RIP cigarettes be made mandatory.18 
Performance standards for cigarettes 
WHO TobReg has also recommended that a new machine smoking regimen be agreed for 
cigarettes which would give a better characterisation of cigarette smoke and that this 
should be used to set product performance standards for cigarettes.18 The group has 
suggested setting limits for eight constituents per mg of nicotine in tobacco smoke 
emissions18; these compounds were selected based on known toxicity, variation in 
concentration across brands, the potential for the toxin to be reduced in cigarette smoke 
using existing methodologies, and the need to have constituents that represented gas and 
particulate phases of smoke and different chemical and disease families. While tying the 
emission reductions to nicotine delivery should reduce compensation, it is unknown 
whether reducing or removing individual known toxins in cigarettes will produce marked 
reductions in smoking related diseases.19 
Reducing attractiveness 
Attractiveness has been defined simply as the stimulation to use a product20 and hence the 
public health rationale for this approach is to reduce the consumer appeal of tobacco 
products which in turn could reduce youth uptake, repeat usage or facilitate cessation. In 
the last few years, steps have been taken to remove some types of flavoured cigarettes 
(table 1), but menthol is currently excluded from such laws. An expert scientific advisory 
committee in the USA has reported that removing menthol cigarettes from the market 
would benefit public health21 and the FDA is currently considering what action, if any, to 
take in response to this report. The partial guidelines for Articles 9 and 10 recommend the 
prohibition or restriction of several types of ingredients (table 1). The introduction of plain 
packaging, given the appeal of branded cigarettes, is also likely to have an impact on 
reducing the attractiveness of cigarettes, particularly to children.  
Reducing nicotine dependence/abuse liability 
Relatively little focus has been given to this area of regulation. There are criteria for 
assessing addictiveness (or misuse liability) in animals, but not currently in humans20 
although recent reviews have identified processes for doing this.22 23 The addictiveness of 
tobacco products is linked to the dose and speed of nicotine delivery and it has been 
suggested that tobacco products can be made less addictive and possibly ‘non-addictive’ by 
reducing the nicotine content of cigarettes (ie, the amount of nicotine contained in the 
tobacco itself).24 This strategy merits further research as tobacco companies have explored 
nicotine thresholds,25 and it may be an easier strategy to adopt than one aimed at reducing 
harm. However, we believe that there is currently insufficient evidence and experience with 
this approach given the substantial risks of adopting such a strategy: concerns remain about 
compensatory smoking; nicotine has been shown to exert effects at relatively low levels and 
there is likely to be individual variability in any nicotine ‘threshold’ level of addictiveness; 
and the lure of black market cigarettes having higher nicotine levels.24 26 27 Notably, 
cigarettes such as Vector Tobacco's QUEST that have used genetically modified tobacco 
which is nicotine free, have not proved to be popular.  
Regulating substances in tobacco other than nicotine could also reduce the addictiveness of 
cigarettes.1 Whereas individual additives have not yet been identified as addictive, additives 
could give rise to other addictive substances, or impact on pH or ease of inhalation and 
thereby indirectly enhance addiction.20 Some cigarettes are already marketed by the 
industry as 100% additive free, but there is no evidence to suggest that these are less 
harmful or addictive than traditional cigarettes.  
Non-combustible tobacco products 
The regulation of non-combustible tobacco products is more variable between countries 
than combustibles, including outright bans for some product categories and voluntary 
controls on toxin constituents (table 1). The FCTC partial guidelines for Articles 9 and 10, 
governing the regulation of ingredients and flavours, apply to all tobacco products and so 
include smokeless tobacco.  
Non-combustible tobacco covers a heterogeneous array of products, such as chewing 
tobacco and oral snuff. Product innovation is also common in the non-combustible tobacco 
market, with a plethora of new brands and products being recently launched, often bearing 
well known cigarette brand names, such as Camel Orbs, sticks and strips. Non-combustible 
tobacco products vary greatly in their manufacture and content and there is good evidence 
of differences in health outcomes resulting from the use of different products.28 It is 
believed that quantities of two main carcinogens, tobacco specific N-nitrosamines (TSNAs) 
and polycyclic aromatic hydrocarbons (PAHs) are responsible for the differences in health 
outcomes across smokeless tobacco products.29 30 WHO TobReg has proposed specific limits 
for the concentration of three toxins in the dry weight of tobacco in smokeless products31 
and suggested that regulatory efforts be focused initially on the larger manufacturers, but 
with a parallel process to educate smaller cottage industries how to manufacture and store 
compliant products. We support this strategy.  
Regulating non-combustible tobacco to reduce the concentrations of the most harmful 
toxins could also improve the potential for harm reduction if smokers can be encouraged to 
switch from cigarettes to smokeless products. Evidence from Sweden clearly shows how the 
use of snus (a low nitrosamine oral snuff product) instead of cigarettes can lead to lower 
overall harm, reduced initiation and increased cessation of cigarettes.32 
Lessons learnt and issues under debate 
Overall, the above examples illustrate different approaches to tobacco product regulation 
being adopted worldwide, often driven by the tobacco industry with no regulatory 
oversight. The lack of a clear, regulator-led internationally agreed and articulated strategy is 
apparent, unlike in other areas of tobacco control, but the adoption of partial guidelines for 
Articles 9 and 10 of the FCTC now paves the way for the development of such a global 
strategy.  
Misrepresentation of risks 
A key lesson from early product regulatory efforts is the potential dangers of any tobacco 
marketing and communications of altered tobacco products that can falsely reassure and 
lead to continued tobacco use. A clear distinction therefore needs to be made between any 
changes made to products and communicating these changes to consumers. To enable this 
to happen, all marketing of tobacco products should be prohibited to ensure that only 
regulators communicate with tobacco users about differential risks and avoid the industry 
misusing regulation to promote their products. Given the evidence that pack imagery, 
colours and design suggest differential risks to consumers, and can increase appeal of 
tobacco products and smoking (eg, Hammond et al33), we also believe that plain packaging 
should be urgently introduced across all tobacco products.  
Measuring impact 
Another key lesson from the ‘tar reduction’ strategy was that the public health community 
was slow to recognise the limitations of the approach despite early evidence that filter 
venting was an ineffective method of reducing exposure to smokers.2 Hence, it took some 
time to realise that the health benefits were not forthcoming. This underscores the dangers 
involved in all product regulatory approaches aimed at reducing harm to users, as diseases 
caused by tobacco use can take up to two decades to develop, an issue not affecting other 
tobacco control strategies that are aimed at either reducing initiation or increasing cessation 
(and hence have more easily measureable outcomes over relatively short timescales). 
Biomarkers are measures of exposure to different elements of tobacco or tobacco smoke, or 
precursors of disease, and these can be tracked over time or compared across different 
tobacco products, hence offering quicker feedback as indicators of reduced harm. A recent 
review34 concluded that biomarker testing in large studies of smokers is now feasible and 
should be prioritised, enabling, over a few decades, the identification of the best biomarkers 
to use as interim measures to predict tobacco-related disease. Ultimately, the selected 
biomarkers could then be used to test the introduction of PREPs or modified tobacco 
products. Given the costs of introducing such biomarker testing and the large numbers of 
tobacco users needed, this approach is likely to exceed the resources available in most 
countries.  
Measurement, monitoring and evaluation 
An adequate surveillance and feedback system is required to enable regulators to monitor 
the impact of tobacco products on prevalence, initiation, harm and particularly unintended 
outcomes.35 Before such a system can function, mandatory reporting regulations for all 
nicotine and tobacco products on the market are necessary as adopted by Canada (table 1) 
and set out in Articles 9 and 10. Mandatory reporting should include design components 
(eg, filter ventilation level, paper porosity, etc), tobacco constituents, emissions for 
combustible products, as well as measures of abuse liability.  
Such regulations, however, require substantial investment of human and financial resources 
even where the financial costs are borne by the tobacco industry (as recommended in the 
guidelines for Articles 9 and 10). As regulatory capacity for tobacco is very limited in the vast 
majority of countries worldwide, we are concerned that tobacco product regulation has 
enormous opportunity costs and could detract from implementing other evidence-based 
tobacco control strategies. Regulatory capture by the tobacco industry is also a risk. The 
complexity of tobacco products also requires knowledge and skills ranging across toxicology, 
pharmacology, biochemistry, psychology and behaviour change; the long history of denial 
and deception by the tobacco industry indicates that regulators cannot rely on industry 
information alone and will need to validate information provided to them. The working 
group set up for Articles 9 and 10 was asked to consider the development of an 
independent Global Data Repository to facilitate tobacco product regulation worldwide36 
but it is not clear how or if this will be taken forward. We believe that such a repository is a 
prerequisite for implementing Articles 9 and 10 and while initially focusing on product data 
(eg, content, design and emissions), it could be expanded to include other data (such as 
toxicity and sales data) and underpin other FCTC Articles. The repository would ease the 
burden on regulators as data would be collected and analysed, enabling comparisons to be 
made globally; information would then be relayed to national regulators with 
recommendations in an easily understandable form. This could build on existing research 
and templates37–39 and incorporate the comprehensive testing programme set out in a 
recent review.40 
The challenge of reducing the risk of cigarettes 
Making combustible tobacco products less harmful is not straightforward because the 
relationships among unburnt content, the products of pyrolysis and toxicant exposure are 
not well established. Given that tobacco smoke consists of over 4000 constituents, with 60 
of these known carcinogens, care needs to be taken to ensure that decreasing the content 
of 1 or more carcinogens does not increase the concentration of other carcinogens in the 
smoke. For these reasons, we are cautious about strategies to limit specific toxic emissions 
for cigarette smoke.  
Instead, some strategies to reduce the attractiveness of cigarettes could have a more 
marked effect on public health and be introduced relatively easily, the most obvious one 
being the introduction of generic packaging. Strategies to reduce the addictiveness of 
cigarettes are currently in their infancy.  
The importance of coregulation 
Focusing on the much greater differential risks among classes of tobacco and nicotine 
products, such as among smoked tobacco, smokeless tobacco and medicinal nicotine 
products, is likely to be a more promising strategy.41–43 However, the wide range of harms 
across the non-combustible tobacco products and the long history of deception and 
aggressive marketing strategies of the tobacco industry have led to deep distrust by many in 
the tobacco control movement. There has therefore been reluctance to acknowledge the 
differential health risks44 and the role that regulated smokeless tobacco products could play 
in a harm reduction strategy.45 This has been an area of much divisive debate among 
tobacco control advocates and as a result regulatory strategies have rarely looked across all 
tobacco products and developed regulations commensurate to differential harmfulness.  
The plethora of nicotine and tobacco products now being marketed does, however, suggest 
that serious consideration could now be given to prohibiting combustible tobacco over a 
specified time period,27 perhaps by capping smoked tobacco46 47 while incentivising cleaner 
nicotine products42 43 (and possibly highly regulated smokeless tobacco products47). 
Premarket applications should therefore only be given to tobacco products that 
demonstrate reduced risk, appeal, or addictiveness for which global standards should 
ultimately be set through the FCTC processes. While non-tobacco products are outside the 
scope of this paper, we believe that they hold much greater potential for harm reduction 
than those involving tobacco, as witnessed by the rapid increase in public interest in 
electronic cigarettes.48 Regulators in the UK and New Zealand are beginning to look at 
nicotine products and appropriate regulations for them.49 Such a strategy raises ethical 
dilemmas including whether the use of clean but addictive nicotine products would be an 
acceptable end point. Tobacco control advocates need to engage actively with consumers as 
the voice of the consumer has often been appropriated by the tobacco and other industries 
(eg, FOREST50).  
In addition to product regulation, regulation of the whole tobacco and nicotine industry 
should be considered (eg, Sugarman, Hall and Gartner and Borland46 47 51). However, as yet 
no country has seriously considered this. Following examples from other areas, such as the 
use of leaded petrol or medicines, manufacturers are unlikely to introduce meaningful steps 
to make their products less harmful without goals and targets being set for the whole 
industry.  
Conclusions and next steps 
Cigarettes are the most prevalent and deadly form of tobacco use worldwide and it is not 
yet known if and how they can be made significantly less harmful. Any reductions in health 
risk from regulating cigarettes are likely to be small and will take a long time to achieve. We 
believe that the time has come to abandon the notion of safe or safer cigarettes. Tobacco 
product regulation has huge opportunity costs and given the range of harms across the 
nicotine and tobacco product spectrum, we believe a better strategy for regulators is to 
assess the feasibility of setting a goal to end the sale of combustible tobacco use over a 
given period of time24 and move customers towards less harmful nicotine products as soon 
as possible. While smokeless tobacco products could be used for those who will not stop 
smoking or switch to clean nicotine products, we believe that there is no appetite for any 
sort of promotion of smokeless tobacco products currently in the public health community 
given the divisions in opinion on this issue, but research and debate on this should continue. 
Regulations that would remove or dramatically alter conventional cigarettes or other widely 
used tobacco products may also have implications for contraband tobacco, although this 
would largely depend upon the jurisdiction and the scope of the regulatory change.  
The removal of combustible tobacco products should be done in parallel with efforts to: 
restrict attractiveness of all tobacco products (eg, introducing generic packaging); forbid all 
marketing of tobacco products to ensure that only regulators communicate with tobacco 
users about relative risks; introduce toxin limits for smokeless tobacco products; forbid the 
introduction of any new, or changes to existing, products without prior notification and 
demonstrable reduction in harm, attractiveness and/or addictiveness; forbid the 
introduction of new combustible products which are ‘substantially equivalent’; and 
introduce a global, tobacco industry resourced but industry independent, FCTC data 
repository to guide international strategy in this area.  
What this paper adds 
• There are many pitfalls involved in tobacco product regulation including the long 
time lag before health impacts become apparent, the danger of consumers deriving 
false health reassurances and the opportunity costs of implementing resource-
intensive product regulatory strategies.  
• The goal of producing safer cigarettes should be abandoned and instead regulators 
should set a goal over a period of time to end the sale of combustible tobacco and 
consider a comprehensive nicotine regulation strategy that moves smokers who 
cannot or will not quit towards less harmful nicotine products as quickly as possible.  
• Product regulation should reduce the appeal of tobacco products and prevent new 
tobacco products/brand variants from being marketed without evidence of reduced 
harm, appeal or addictiveness.  
• An independent, but industry resourced, global repository should be set up to assist 
national regulators in understanding and regulating the products on their markets.  
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